JAK Inhibitor Comes Up Short in Phase III Crohn's Disease Trial

(MedPage Today) -- An investigational oral Janus kinase (JAK) inhibitor failed to meet most primary endpoints in a phase III trial of patients with moderate to severe Crohn's disease, but the failures might have been due to problems with study...